Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus. - Full Text View

Sponsor:	Takeda Italia Farmaceutici S.p.A.
Information provided by:	Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier:	NCT00770835

Purpose

The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.

Condition	Intervention	Phase
Diabetes Mellitus	Drug: Pioglitazone, Metformin and Lifestyle Modification Drug: Glibenclamide, Metformin and Lifestyle Modification	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	Effects of Pioglitazone on Endothelial Progenitor Cells in Type 2 Diabetic Patients With Vascular Complications - The SPLENDOR Study.

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Glyburide Pioglitazone Pioglitazone hydrochloride Metformin Metformin hydrochloride

U.S. FDA Resources

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:

Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+). [ Time Frame: Final Visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change from Baseline in Circulating Progenitor Cells Integrated Markers of cardiovascular risk (CD34+). [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]
Change from Baseline in Flow Mediated Dilation Integrated Markers of cardiovascular risk. [ Time Frame: Final Visit. ] [ Designated as safety issue: No ]
Modulation of Endothelial Progenitor Cell recruitment (vascular endothelial growth factor, erythropoietin and stromal cell-derived factor-1). [ Time Frame: Weeks: 4, 12 and 24. ] [ Designated as safety issue: No ]
Measure of Glucose Control (glycosylated hemoglobin and fasting plasma glucose). [ Time Frame: Weeks: 4, 12 and 24. ] [ Designated as safety issue: No ]
Measure of Lipid Parameters (total lipids, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein B and apolipoprotein A1). [ Time Frame: Weeks: 4, 12 and 24. ] [ Designated as safety issue: No ]
Change from Baseline in lipid parameters (free fatty acids and oxidized low-density lipoprotein). [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]
Change from Baseline in insulin sensitivity (insulin indexes by 2 hour oral glucose tolerance test with glucose, insulin and C-peptide estimation). [ Time Frame: Final Visit. ] [ Designated as safety issue: No ]
Change from Baseline in Inflammation Markers (high-sensitivity C-reactive protein, IL-6, vascular adhesion molecules (E-selectin, vascular cell adhesion molecule-1), monocyte chemotactic protein-1 and tumor necrosis factor-alpha). [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]
Change from Baseline in Adipokines (adiponectin). [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]
Change from Baseline in Oxidative Stress (maleic dialdehyde, ferric reducing antioxidant power and lipid hydroperoxide. [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]
Urinary albumin excretion. [ Time Frame: Weeks: 12 and 24. ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	March 2009
Estimated Study Completion Date:	February 2010
Estimated Primary Completion Date:	February 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Pioglitazone, Metformin and Lifestyle Modification Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
2: Active Comparator	Drug: Glibenclamide, Metformin and Lifestyle Modification Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.

Detailed Description:

Diabetes is one of the most common chronic diseases worldwide, affecting nearly 200 million people, almost all suffering from Type 2 Diabetes. It is the fourth leading cause of death in developed countries due to the negative impact of the disease on the cardiovascular system. Treatment, aimed to the reduction of this intrinsic cardiovascular risk, is based on tight control of glucose and all coexisting metabolic abnormalities as well as of biomarkers of inflammation and atherogenesis.

Macrovascular complications account for the vast majority of morbidity and mortality in diabetic patients, and there is growing evidence that pathophysiologic mechanisms other than hyperglycemia are responsible. The condition of the vascular endothelium in particular has been shown to effect the health and disease of the cardiovascular system.

The number and function of endothelial progenitor cells correlate inversely with cardiovascular risk factors and may be a surrogate biologic marker for vascular function and cumulative cardiovascular risk.

Pioglitazone is an orally active thiazolidinedione derivative. It is a ligand for peroxisome proliferator-activated receptor-gamma activation that alters transcription of various genes regulating carbohydrate and lipid metabolism.

Eligibility

Ages Eligible for Study:	40 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Females must be non-pregnant, non-lactating and post-menopausal.
A glycosylated hemoglobin level greater than 7.5% and less than 10%.
Has an age of onset of Type 2 Diabetes greater than 35 years of age.
Is on metformin monotherapy up to the maximum tolerated daily dose.
Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.
Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.
Has one or more cardiovascular comorbidities as follows:
- stable angina pectoris
- previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography
- peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.

Exclusion Criteria:

Has Type 1 Diabetes.
Is on insulin therapy.
Is severely obese defined as a body mass index greater than or equal to 40mg/m2
Has diabetic retinopathy.
Has evidence of hepatic dysfunction including liver transaminase greater than three times the upper limit of normal.
Is unable to remain on a stable dose of the following class of medications 30 days prior to randomization and throughout the six months of the study:
- antihypertensives
- statins
- other hypolipidemic and antiplatelet drugs
Has a history of alcohol or other drug abuse.
Has had a new diagnosis of cancer or recurrent cancer within five years of screening.
Has a need for chronic (greater than two weeks) immunosuppressive therapy.
Has had heart failure based on the New York Heart Association Functional Class I through IV.
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Other antidiabetic drugs (except metformin)
- Fibrates
- Rifampicin
- Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents
- Other drugs that are highly protein bound, including:
  - sulphonamides
  - chloramphenicol
  - probenecid
  - monoamine oxidase inhibitors
  - fluoroquinolones antibiotics
  - oral miconazole
Has participated in another clinical study within the past three months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770835

Contacts

Contact: Study Manager

+39 0295-794357

Locations

Italy
	Recruiting
Pisa, Italy
	Recruiting
Padova, Italy

Sponsors and Collaborators

Takeda Italia Farmaceutici S.p.A.

Investigators

Study Director:

Medical Director

Takeda Italia Farmaceutici S.p.A.

More Information

Additional Information:

ACTOS® Package Insert This link exits the ClinicalTrials.gov site

FDA Safety Alerts and Recalls This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Takeda Italia Farmaceutici S.p.A. ( Medical Director )
Study ID Numbers:	IT-PIO-109, 2007-003077-44
Study First Received:	October 8, 2008
Last Updated:	October 5, 2009
ClinicalTrials.gov Identifier:	NCT00770835 History of Changes
Health Authority:	Italy: Ministry of Health

Keywords provided by Takeda Global Research & Development Center, Inc.:

Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes

Diabetes Mellitus, Lipoatrophic
Dyslipidemia
Drug Therapy

Additional relevant MeSH terms:

Glyburide
Hypoglycemic Agents
Metabolic Diseases
Pioglitazone
Physiological Effects of Drugs
Metformin

Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010